A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin,and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2014
At a glance
- Drugs Pemetrexed (Primary) ; Bevacizumab; Cisplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 28 Jan 2014 Status changed from active, no longer recruiting to completed according to European Clinical Trial Database Record .
- 24 Dec 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 13 Mar 2013 Planned End Date changed from 1 Mar 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.